| Position | Action |
|---|---|
| Overweight vs. mandate and price rallies to $64-65 | Trim into relief rally in tranches (10-15% sized trims) |
| Price pulls back to $62-63 on declining volume and holds | Viable high-conviction entry for new positions |
| Price closes below $58.44 on expanding volume | Reactivate Underweight; confirms bear distribution thesis |
BMY is a $49B revenue, $18.9B EBITDA, $8.1B free cash flow machine trading at 9.88x forward earnings with a 3.93% dividend yield, a confirmed golden cross on the technicals, and a management team actively deleveraging the balance sheet while deploying AI to accelerate a pipeline.
| Indicator | Value | Signal |
|---|---|---|
| 10 EMA | $63.96 | bullish |
| 50 SMA | $58.44 | bullish |
| 200 SMA | $55.09 | bullish |
| MACD Line | 1.92 | neutral |
| MACD Signal Line | 1.86 | — |
| MACD Histogram | +0.06 | bearish |
| RSI (14) | 63.57 | neutral |
| RSI Peak | 72.79 (2026-08-04) | neutral |
| Bollinger Upper Band | $67.22 | — |
| Bollinger Middle (20 SMA) | $62.25 | neutral |
| Bollinger Lower Band | $57.28 | — |
| ATR (14) | $1.86 | neutral |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
Hold at current weight; no new longs at spot ($64.72) as stretched technicals collide with deferred Eliquis LOE catalysts
Hold BMY rather than Underweight because: (a) 1.57x FCF dividend coverage means income accounts should hold full size; (b) the technical regime change is real (golden cross confirmed, 200 SMA rising from $46 to $55, VWMA at $64.03); (c) EPS revision risk is bilateral ($5.20-$6.55) and doesn't yet justify reducing exposure; (d) the Eliquis LOE is already priced in at the 9.88-12.4x multiple, not a fresh risk. Hold rather than Buy because: (a) realistic drawdown if $62.25 breaks is $6.28 (9.7%) to the 50 SMA, not the $2.47 in the aggressive analyst's math; (b) cooling momentum signals make spot entry a momentum chase; (c) AI narrative lacks earnings validation; (d) consensus revision risk remains elevated.
When: Price retests breakout level with volume confirmation
Then: Reassess for potential entry closer to structural support
Technical golden cross is structural, not momentum overshoot; August 3rd volume (32.97M shares) confirms breakout validity
↩ rebuts: “Bear's claim that price is stretched and vulnerable to mean-reversion”
· concedes: Chasing at $64.72 is poor risk/reward — pullback to $62.00-$62.25 is the preferred entry; Eliquis patent cliff is a real risk (15-20% revenue compression in 2027) but already priced into 9.88x P/E; Q4 2025 had $1.6B restructuring charge; Q2 2025 had $2.1B impairment that compressed base; Opdivo losing share to Keytruda is a real concern, though subcutaneous formulation and combo regimens provide stability; Acquisition integration risk (Karuna/Mirati/RayzeBio) is legitimate; Debt-to-Equity at 201.9x appears alarming (though acknowledged as buyback artifact)
BMY appears cheap at 9.88x forward P/E only because the consensus EPS estimate of $6.55 assumes flawless pipeline execution while ignoring realistic Eliquis erosion; the stock faces a $13B+ patent cliff starting 2026-2027, an unproven acquisition-heavy pipeline (Karuna/Mirati/RayzeBio representing ~$22.9B in goodwill), $45B in remaining debt with limited deleveraging FCF, and a technically extended setup with momentum fading and volume distribution — making this a value trap rather than a bargain.
· concedes: If Eliquis LOE gets pushed out by patent litigation, BMY re-rates higher; Pipeline could exceed expectations with Cobenfy ramping faster than anticipated and MRTX1719 hitting in KRAS; Technical setup could be validated if price retests and holds $60 breakout level with renewed volume
→ vs conservative: Anchoring to 12.4x P/E on $5.20 EPS is backward-looking; market is pricing $6.55 forward EPS at 9.88x
→ vs conservative: Net debt reduction of $5.9B YoY, 74% working capital increase, and 1.57x FCF dividend coverage contradict 'preserve not optimize' framing
→ vs conservative: Eliquis LOE bear case is priced in (9.88x vs potential 15x) and fight is already over
→ vs conservative: AI productivity narrative and Cobenfy/MRTX1719 pipeline justify multiple expansion beyond backward-looking benchmarks
→ vs neutral: RSI cooling from 72 to 63 and below-average volume signal accumulation, not distribution—the largest volume spike in 19 months validates breakout
→ vs neutral: Waiting for $62.25 pullback assumes institutional breakout confirmation (33M shares) will hand retail free reload; structurally unlikely with 200 SMA rising $1.50/month
→ vs neutral: Zero retail engagement (no Reddit/StockTwits) represents institutional accumulation opportunity, not low-confidence signal
→ vs neutral: Defensive characteristics (beta 0.225, 3.93% yield) are reasons to overweight in risk-on, zero-cut macro regime, not hold
| VWMA (20) | $64.03 | bullish |
| Golden Cross | 50 SMA crossed above 200 SMA (early-to-mid 2026) | bullish |
Support: 57.28 · 58.44 · 55.09 · 62.25 | Resistance: 65.89 · 67.22 · 68.1
BMY exhibits a strong bullish technical setup with price ($64.72) well above all major moving averages and a confirmed golden cross, but near-term momentum is decelerating as MACD histogram shrinks and RSI pulls back from 72.79 overbought levels. Volume confirmation is positive (VWMA aligned with price), though today's volume of 7.04M was below average, and Bollinger Bands are expanding (indicating heightened volatility). The overall bias remains bullish with support at $62.25 and $58.44, but analysts recommend existing holders maintain positions with trailing stops while new buyers await pullbacks to the $62.00-$62.50 entry zone for better risk/reward.
Market Cap
$132.2 B
P/E (TTM)
14.26x
Forward P/E
9.88x
PEG Ratio
2.44
P/B
5.92x
EPS (TTM)
$4.54
Forward EPS
$6.55
Dividend Yield
3.93%
Beta
0.225
52-Week Range
$42.52 – $68.10
50-Day Avg
$58.26
200-Day Avg
$55.67
Revenue (TTM)
$49.19 B
Gross Profit
$35.25 B
Gross Margin
~71.7%
Operating Margin
34.42%
EBITDA
$18.93 B
Net Income
$9.28 B
Profit Margin
18.87%
ROE
46.60%
ROA
10.72%
Free Cash Flow (TTM)
$8.11 B
Dividends Paid
$1.29 B per quarter
Dividend Coverage by FCF
1.57x
CapEx
$300-370M per quarter
Total Assets
$87.63 B
Stockholders' Equity
$22.32 B
Total Debt
$45.05 B
Net Debt
$34.40 B
Cash & Equivalents
$8.72 B
Working Capital
$9.92 B
Goodwill
$21.74 B
Other Intangibles
$17.63 B
Tangible Book Value
-$17.05 B
Debt-to-Equity
201.9x
Net Debt / EBITDA
~1.82x
Current Ratio
1.532
Q2 2026 Revenue
$12.97 B
Q2 2026 Net Income
$3.32 B
Q2 2026 Diluted EPS
$1.62
Q2 2026 Operating CF
$3.39 B
Q2 2026 Free Cash Flow
$3.09 B
Treasury Stock
$43.5 B
Equity
$22.3 B
Interest Expense
$1.6-1.9B annualized
R&D
$2.6-3.0B per quarter
Strengths
Concerns
BMY presents a value opportunity with a Forward P/E of 9.88x, significantly below historical norms of 12-14x and growth-pharma peers. The company demonstrates strong profitability with 34% operating margins and 18.87% net margins, generating $8.11B in TTM free cash flow that supports both the 3.93% dividend yield and active debt reduction. Q2 2026 results showed 153% YoY EPS growth to $1.62, driven by top-line expansion and new product launches. The balance sheet shows positive deleveraging progress with stockholders' equity rising 28% YoY and total debt declining 11.5%, though the company faces material risks from the Eliquis patent cliff (~$13B in annual sales) and significant debt load of $45B.